Alembic Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis

Share Price NSE
₹763.05
▼ -4.45 (-0.58%)
2026-02-20 00:00:00
Share Price BSE
₹762.90
▼ -4.25 (-0.55%)
2026-02-20 00:00:00
Track Alembic Pharmaceuticals share price live with TickJournal's free stock screener. Analyze Alembic Pharmaceuticals share price history trends and compare 52-week high low levels. Calculate APLLTD stock fair value using fundamental analysis and view live share price charts. Determine Alembic Pharmaceuticals share intrinsic value and compare it with current APLLTD share price. Record your Alembic Pharmaceuticals trades in TickJournal's free trading journal and track your portfolio performance.
EPS (TTM) ₹29.68
Dividend Yield 1.43%
Debt to Equity 0.18
APLLTD 52 Week High ₹1039.10
Alembic Pharmaceuticals 52 Week Low ₹743.65
Operating Margin 15.00%
Profit Margin 8.80%
APLLTD Revenue (TTM) ₹1,784.00
EBITDA ₹286.00
Net Income ₹157.00
Total Assets ₹7,773.00
Total Equity ₹5,190.00

Alembic Pharmaceuticals Share Price History - Stock Screener Chart

Screen APLLTD historical share price movements with interactive charts. Analyze price trends and patterns.

Alembic Pharmaceuticals Company Profile - Fundamental Screener

Screen Alembic Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for APLLTD shares.
Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across...more
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
Chairperson/CEO Chirayu R Amin
ISIN INE901L01018

Alembic Pharmaceuticals Balance Sheet Screener

Screen APLLTD balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Assets
Total Assets 7,773 6,446 6,183 7,122 6,709 5,989 4,778 3,941 2,689 2,429
Current Assets 4,088 3,079 2,910 2,861 2,652 2,463 1,958 1,825 1,373 1,511
Fixed Assets 2,524 2,547 2,398 1,798 1,788 1,552 1,159 993 799 708
Liabilities
Total Liabilities 7,773 6,446 6,183 7,122 6,709 5,989 4,778 3,941 2,689 2,429
Current Liabilities 171 172 175 168 361 1,047 570 576 94 84
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 5,190 4,818 4,371 5,238 5,067 3,190 2,718 2,220 1,902 1,597
Share Capital 39 39 39 39 39 38 38 38 38 38
Reserves & Surplus 5,152 4,779 4,331 5,198 5,028 3,182 2,681 2,182 1,865 1,560

Alembic Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Alembic Pharmaceuticals income statement and profit fundamentals. Analyze APLLTD quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Alembic Pharmaceuticals share price evaluation.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept
Revenue 1,784 1,717 1,919 1,892 1,521 1,564 1,678 1,703 1,407 1,498 1,605 1,634 1,426 1,263 1,475
Expenses 1,498 1,430 1,595 1,627 1,257 1,325 1,409 1,433 1,203 1,288 1,387 1,364 1,268 1,255 1,244
EBITDA 286 287 324 265 263 239 270 270 205 210 218 269 158 9 231
Operating Profit % 15.00% 16.00% 17.00% 13.00% 17.00% 15.00% 15.00% 15.00% 14.00% 13.00% 13.00% 16.00% 10.00% 1.00% 16.00%
Depreciation 69 74 76 80 70 69 71 70 74 66 68 69 123 67 68
Interest 25 24 24 23 11 13 19 22 14 14 16 15 7 9 12
Profit Before Tax 192 190 224 162 183 157 180 178 116 130 135 185 29 -67 151
Tax 35 37 40 30 5 23 27 40 -36 9 -2 4 7 -2 18
Net Profit 157 154 184 132 178 135 153 138 153 121 137 180 22 -66 133
EPS 7.98 7.85 9.40 6.76 9.07 6.84 7.79 7.01 7.76 6.14 6.95 9.23 1.11 -3.35 6.78

Alembic Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen APLLTD cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 88 803 724 552 1,463 449 812 312 329 948
Investing Activities -568 -321 -448 -372 -840 -731 -756 -884 -486 -307
Financing Activities 444 -438 -262 -217 -597 155 59 503 -129 -224
Net Cash Flow -37 45 14 -37 26 -127 115 -69 -286 417

Alembic Pharmaceuticals Shareholding Pattern Screener

See Alembic Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Alembic Pharmaceuticals promoter holding and ownership changes for APLLTD on TickJournal.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec
Promoter Holding 69.67% 69.67% 69.74% 69.74% 69.61% 69.61% 69.61% 69.61%
FII Holding 3.94% 3.96% 4.05% 4.24% 4.46% 4.32% 3.94% 4.17%
DII Holding 16.43% 16.46% 16.30% 16.17% 15.38% 15.47% 16.05% 16.06%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 7.07% 7.01% 6.93% 6.87% 7.41% 7.48% 7.36% 7.26%
Other Holding 2.88% 2.89% 2.99% 2.98% 3.14% 3.13% 3.04% 2.90%
Shareholder Count 91,336 89,013 89,969 87,000 76,567 74,829 91,429 93,944

Alembic Pharmaceuticals Share Dividend Screener - Share Yield Analysis

Check Alembic Pharmaceuticals dividend history with payout and yield data. View Alembic Pharmaceuticals dividend details including ex-dates and amounts for APLLTD stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹11.00 1.43%
2024-March ₹11.00 1.18%
2023-March ₹8.00 0.81%
2022-March ₹10.00 2.13%
2021-March ₹14.00 1.89%
2020-March ₹10.00 1.04%
2019-March ₹5.50 1.03%
2018-March ₹4.00 0.74%
2017-March ₹4.00 0.73%

Alembic Pharmaceuticals Market Events Screener - Corporate Actions

Get Alembic Pharmaceuticals corporate actions including splits, bonuses, and buybacks. Check Alembic Pharmaceuticals stock events that may affect APLLTD share price.
Announcement Date Record Date Event Type Information Price Impact
2026-02-05 2026-02-05 Quarterly Result Announcement NA 3.71%
2025-11-04 2025-11-04 Quarterly Result Announcement NA -0.92%
2025-08-05 2025-08-05 Annual General Meeting NA -1.57%
2025-08-05 2025-08-05 Quarterly Result Announcement NA -6.22%
2025-07-29 2025-07-29 Dividend ₹ 11.00 /share 10.49%
2025-05-06 2025-05-06 Quarterly Result Announcement NA 6.54%
2025-02-03 2025-02-03 Quarterly Result Announcement NA -9.02%
2024-11-07 2024-11-07 Quarterly Result Announcement NA -3.68%
2024-07-22 2024-07-22 Annual General Meeting NA 27.73%
2024-07-15 2024-07-15 Dividend ₹ 11.00 /share -1.72%
2023-07-28 2023-07-28 Dividend ₹ 8.00 /share 30.61%
2022-08-17 2022-08-18 Dividend ₹ 10.00 /share -16.05%
2021-07-19 2021-07-21 Dividend ₹ 14.00 /share -4.47%

Alembic Pharmaceuticals Competitors Screener - Peer Comparison

Screen APLLTD competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 408,007 37.20 54,729 9.71% 10,980 53.25
Divis Laboratories 163,250 66.07 9,712 18.67% 2,191 48.15
Torrent Pharmaceuticals 144,229 64.43 11,539 6.99% 1,911 70.35
Cipla 109,566 23.71 28,410 7.12% 5,291 45.95
Dr Reddys Laboratories 105,948 19.16 33,741 16.73% 5,725 58.53
Lupin 101,478 21.52 22,910 13.74% 3,306 60.82
Zydus Life Science 91,613 18.12 23,511 18.55% 4,615 52.96
Mankind Pharma 86,000 47.17 12,744 20.90% 2,007 45.43
Aurobindo Pharma 68,802 19.14 32,346 9.43% 3,484 51.95
Alkem Laboratories 65,528 26.80 13,458 3.70% 2,216 40.44

Alembic Pharmaceuticals Company Announcements - News Screener

Screen APLLTD latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-02-17 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View
2026-02-17 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2026-02-12 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2026-02-12 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2026-02-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome View
2026-02-05 Announcement under Regulation 30 (LODR)-Change in Directorate View
2026-02-05 Announcement under Regulation 30 (LODR)-Investor Presentation View
2026-02-05 Unaudited Financial Results For Quarter And Nine Months Ended 31St December 2025 View
2026-02-05 Announcement under Regulation 30 (LODR)-Investor Presentation View
2026-02-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2026-02-05 Board Meeting Outcome for Outcome Of Board Meeting View
2026-02-03 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2026-01-31 Announcement under Regulation 30 (LODR)-Change in Management View
2026-01-27 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2026-01-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2026-01-20 Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2025 View
2026-01-12 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2026-01-05 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 View
2025-12-26 Closure of Trading Window View
2025-12-18 Announcement under Regulation 30 (LODR)-Press Release / Media Release View